Annovis Bio Inc. (ANVS): Price and Financial Metrics


Annovis Bio Inc. (ANVS): $109.44

-2.80 (-2.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANVS Stock Price Chart Interactive Chart >

Price chart for ANVS

ANVS Price/Volume Stats

Current price $109.44 52-week high $132.00
Prev. close $112.24 52-week low $4.14
Day low $109.00 Volume 779,000
Day high $117.86 Avg. volume 795,644
50-day MA $83.46 Dividend yield N/A
200-day MA $32.83 Market Cap 760.28M

Annovis Bio Inc. (ANVS) Company Bio


Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.


ANVS Latest News Stream


Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream


Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about Annovis Bio Inc that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

5 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market

Terminator3D/iStock via Getty Images Earlier this year, we wrote that Cassava Sciences (SAVA) could be the best performing stock of 2021. Cassava is up quite a bit since then, but we think it still has a very long way to go. Here are five reasons why. 1) No Disease-Modifying Therapies...

Joe Springer on Seeking Alpha | July 27, 2021

AAIC 2021: What to look for at Alzheimer's biggest annual conference

knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to major stock swings. This year's conference comes less than...

Seeking Alpha | July 24, 2021

Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch

Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.

Yahoo | July 23, 2021

Annovis Bio to Present New Data at 2021 Alzheimer's Association International Conference

New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28. A poster presentation featuring positive clinical outcome data from the Company's two Phase 2a studies will be available on Monday, July 26 Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, wi

Yahoo | July 23, 2021

Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022

Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's (NYSE: ANVS) Phase 2 Alzheimer's disease trial evaluating ANVS401. The DSMB has approved the study to proceed with Cohort 3, the final cohort of the study. Funding for this research was provided by a grant from the National Institutes on Aging. The study is run by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine. The safety e

Yahoo | July 20, 2021

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo 25.07%
3-mo 385.11%
6-mo 996.59%
1-year 1,764.40%
3-year N/A
5-year N/A
YTD 1,351.46%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.601 seconds.